|
|
 |
|
Viewing report
|
|
|
|
LATUDA: Another Treatment Option for Schizophrenia
GlobalData, Nov 2010, Pages: 4
LATUDA: Another Treatment Option for Schizophrenia
Summary
The global schizophrenia market in 2009 was valued at approximately $6.7billion. The approved antipsychotic drugs include Abilify (aripiprazole), Zyprexa (olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), Invega (paliperidone), Fanapt (iloperidone) and Saphris (asenapine). The market is forecast to decline to $5.4 billion by 2017 at 3% CAGR. This is due to patent expiry of existing drugs such as Zyprexa, Seroquel, Abilify, Invega and Geodon through to 2014. LATUDA is another treatment option which is likely to be introduced in 2011
Scope
The report provides Our viewpoint on LATUDA, a treatment option for schizophrenia. The scope includes:
- Annualized global schizophrenia market revenues data from 2009 to 2017
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Analysis of the current market for schizophrenia, need for another treatment option
- The impact of LATUDA on the schizophrenia market
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design strategies for the future market
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia market
- Formulate effective sales and marketing strategies in order to keep pace with the possible changes in the market after the introduction of LATUDA in the market
|
|
|
|
